Loss of p53 Attenuates the Contribution of IL-6 Deletion on Suppressed Tumor Progression and Extended Survival in Kras-Driven Murine Lung Cancer

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation | Tan, X., J. Carretero, Z. Chen, J. Zhang, Y. Wang, J. Chen, X. Li, et al. 2013. “Loss of p53 Attenuates the Contribution of IL-6 Deletion on Suppressed Tumor Progression and Extended Survival in Kras-Driven Murine Lung Cancer.” PLoS ONE 8 (11): e80885. doi:10.1371/journal.pone.0080885. http://dx.doi.org/10.1371/journal.pone.0080885. |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------thor link | http://dx.doi.org/10.1371/journal.pone.0080885 |
| Published Version | doi:10.1371/journal.pone.0080885 |
| Citable link | http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879108 |
| Terms of Use | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
Loss of p53 Attenuates the Contribution of IL-6 Deletion on Suppressed Tumor Progression and Extended Survival in Kras-Driven Murine Lung Cancer

Xiaohong Tan1,2,3,*, Julian Carretero2,3,*, Zhao Chen2,3, Jishuai Zhang1, Yanxiao Wang1, Jicheng Chen1, Xiubin Li1, Hui Ye1, Chuahao Tang3, Xuan Cheng1, Ning Hou1, Xiao Yang1,4, Kwok-Kin Wong2,3,6,7,8

1 State Key Laboratory of Proteomics, Genetic Laboratory of Development and Diseases, Institute of Biotechnology, Beijing, China, 2 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, 3 Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America, 4 Model Organism Division, E-institutes of Shanghai Universities, Shanghai Jiao Tong University, Shanghai, China, 5 Department of Lung Cancer, Affiliated Hospital of Academy of Medical Sciences, Beijing, China, 6 Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, 7 Ludwig Center at Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, United States of America, 8 Belfer Institute for Applied Cancer Science, Boston, Massachusetts, United States of America, 9 Department of Physiology, Faculty of Medicine and Odontology, University of Valencia, Valencia, Spain

Abstract

Interleukin-6 (IL-6) is involved in lung cancer tumorigenesis, tumor progression, metastasis, and drug resistance. Previous studies show that blockade of IL-6 signaling can inhibit tumor growth and increase drug sensitivity in mouse models. Clinical trials in non-small cell lung cancer (NSCLC) reveal that IL-6 targeted therapy relieves NSCLC-related anemia and cachexia, although other clinical effects require further study. We crossed IL-6-/- mice with KrasG12D mutant mice, which develop lung tumors after activation of mutant KrasG12D, to investigate whether IL-6 inhibition contributes to tumor progression and survival time in vivo. KrasG12D; IL-6-/- mice exhibited increased tumorigenesis, but slower tumor growth and longer survival than KrasG12D mice. Further, in order to investigate whether IL-6 deletion contributes to suppression of lung cancer metastasis, we generated KrasG12D; p53flox/flox, IL-6-/- mice, which developed lung cancer with a trend for reduced metastases and longer survival than KrasG12D; p53flox/flox mice. Tumors from KrasG12D; IL-6-/- mice showed increased expression of TNFα and decreased expression of CCL-19, CCL-20 and phosphorylated STAT3 (pSTAT3) than KrasG12D-/- mice; however, these changes were not present between tumors from KrasG12D; p53flox/flox, IL-6-/- and KrasG12D; p53flox/flox mice. Upregulation of pSTAT3 and phosphorylated AKT (pAKT) were observed in KrasG12D tumors with p53 deletion. Taken together, these results indicate that IL-6 deletion accelerates tumorigenesis but delays tumor progression and prolongs survival time in a Kras-driven mouse model of lung cancer. However, these effects can be attenuated by p53 deletion.

Citation: Tan X, Carretero J, Chen Z, Zhang J, Wang Y, et al. (2013) Loss of p53 Attenuates the Contribution of IL-6 Deletion on Suppressed Tumor Progression and Extended Survival in Kras-Driven Murine Lung Cancer. PLoS ONE 8(11): e80885. doi:10.1371/journal.pone.0080885

Editor: Victoria Lawson, University of Melbourne, Australia

Received May 29, 2013; Accepted October 8, 2013; Published November 15, 2013

Copyright: © 2013 Tan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work is supported by the NIH (CA122794, CA140594, CA163896, CA166480, CA154303, and Lung SPORE P50CA090578), United Against Lung Cancer, American Lung Association, Susan Spooner Research Fund (KKW), Chinese National Key Program on Basic Research (2012CB945100, 2011CB504202) and National Natural Science Foundation of China (31030040). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

* E-mail: kwong1@partners.org (KKW); yangx@nic.bmi.ac.cn (XY)

These authors contributed equally to this work.

Introduction

Accumulating evidence indicates that inflammation contributes to tumorigenesis, tumor progression, and metastasis [1,2]. Oncogene-associated inflammation leads to production of inflammatory cytokines such as interleukin-6 (IL-6) [3,4], a pleiotropic cytokine involved in inflammation, immunity, bone metabolism, neural development, reproduction, and hematopoiesis [5]. However, IL-6 is also associated with
debilitating cancer-related symptoms such as fatigue, thromboembolism, cachexia, and anemia [3], and IL-6 signaling activation correlates with lung cancer chemotherapy resistance [16,24]. These studies suggest an important role for IL-6 in several aspects of lung cancer.

IL-6 expression can be detected in lung tumors [25] and in 53% of lung cancer cell lines [26], and IL-6 pathways are activated in a human lung cancer stem cell line [27-29]. Functional assays suggest that IL-6 influences the ability of cancer cells to metastasize to distant sites [30,31] and that IL-6 promotes tumor growth in a paracrine fashion in vivo [4,26,32]. Therefore, it is perhaps not surprising that IL-6 knockdown, genetic ablation, or treatment with a neutralizing IL-6 antibody inhibits tumor growth in vivo [4,33]. Conversely, activation of IL-6 signaling contributes to resistance to epidermal growth factor receptor (EGFR) inhibitors in a mouse model of NSCLC [34,35], while blockade increases drug sensitivity in xenograft models [34].

An IL-6 monoclonal antibody therapy would be predicted to inhibit the inflammatory microenvironment in lung cancer. One such therapy, ALD518, has undergone preclinical and Phase I and II clinical trials. It appears to be well tolerated and ameliorates NSCLC-related anemia and cachexia [3], although the totality of clinical outcomes needs further study.

To assess the contribution of IL-6 signaling inhibition on tumor progression and survival time in vivo, we crossed IL-6-/- mice with mutant KrasG12D mice because IL-6 is a downstream effector of oncogenic Ras to promote tumorigenesis[4]. NSCLC is often diagnosed with metastasis and has a poor prognosis. The treatment and prevention of lung cancer metastases are major unmet needs [36]. Inactivating mutations in p53 are found in at least 50% of NSCLC cases [36], and KrasG12D activation accompanied by p53 deletion can cause lung tumor metastasis [37]. To study the function of IL-6 in metastasis, we also generated KrasG12D; p53floxflo, IL-6-/- mice.

Materials and Methods

Mice

IL-6-/- mice were purchased from The Jackson Laboratory and maintained in sterile housing [38]. Conditional Lox–Stop–Lox KrasG12D (hereafter referred to as KrasG12D) mice [39] and p53floxflo mice [40] were described previously. KrasG12D and KrasG12D; IL-6-/- mice were inoculated with 5 x 103 PFU of adenoviral Cre (adeno-Cre) by intranasal inhalation to activate oncogenic KrasG12D in the lungs. KrasG12D; p53floxflo and KrasG12D; p53floxflo, IL-6-/- mice were inoculated with 5 x 103 PFU of adeno-Cre. All experimental procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The protocol was approved by the Institutional Animal Care and Use Committee at Dana-Farber Cancer Institute (permit number 04-094). All surgeries were performed under Avertin anesthesia to minimize suffering. After euthanasia, organs, including heart, liver, spleen, kidney, stomach, intestine, spine, brain, breast, skin, and testis or ovary, were undergone gross inspection for metastases. Lung tumors adhered to the pleura were considered parietal pleural metastases. Suspected metastases were harvested and confirmed by histological features.

Histology and immunohistochemistry

After euthanasia, the lungs were removed and fixed in 10% neutral buffered formalin overnight before embedding in paraffin. Five-micrometer sections of mouse lung tissues were cut. Some sections were stained with H&E. For immunohistochemistry, heat treatment with citrate solution (Beijing ZhongShan Golden Bridge Biotechnology Co., China) in a decloaking chamber (Biocare Medical) unmasked antigens for phosphorylated ERK (pERK), BrdU, Ki67, Endomucin and Caspase-3 staining. Whole lung tissue sections were incubated overnight at 4°C with primary antibodies: pERK (4370, Cell Signaling) at 1:100; BrdU (ab6326, Abcam) at 1:200; Ki67 (ab15580, Abcam) at 1:200; Endomucin (14-5851, eBioscience) at 1:100; cleaved Caspase-3 (9661, Cell Signaling) at 1:300. Digest-All 2B Trypsin (Invitrogen) was used to retrieve the antigen for MAC2 (CL8942AP, Cedarlane) staining at 1:5000. At 400X magnification, all MAC2-positive macrophages in tumors were counted within 3 microscope fields with the most MAC2-positive macrophages after review of the whole lung section. Three mice per genotype were analyzed.

Proliferation analysis

At 20 weeks post-infection, mice were injected intraperitoneally with 10 μL of 10 mM BrdU in PBS per gram of body weight and euthanized after 2 hours. Whole lungs were harvested and processed as described above. At 400X magnification, all BrdU-positive tumor cell nuclei were counted within 3 microscope fields with the most BrdU-positive nuclei after review of the whole lung section. Four mice per genotype were analyzed. Same method was used to calculate Ki67-labeled tumor cells on sections from mice 28 weeks post-infection with adeno-Cre.

Western blotting

Lung tumors were harvested from KrasG12D and KrasG12D; IL-6-/- mice 32 weeks post-infection and from KrasG12D; p53floxflo and KrasG12D; p53floxflo, IL-6-/- mice 15 weeks post-infection for Western blot analysis. Tumors were lysed with a homogenizer in RIPA buffer (50 mM Tris pH 7.4, 150 mM sodium chloride, 1% Nonidet P-40, 0.25% sodium deoxycholate, 1 mM EDTA) containing complete mini protease inhibitors (Roche) and phosphatase inhibitors (5870, Cell Signaling). Nuclear and Cytoplasmic Extraction Kit (CW199B, CoWin Biotech Co., Ltd. China) was used to extract cytoplasmic (C) and nuclear (N) fractions from tumors. Lysates (20 μg per lane) were separated on 10% polyacrylamide gels, transferred to PVDF filters, and incubated overnight at 4°C with antibodies to β-actin (sc-1615, Santa Cruz), pERK (4376, Cell Signaling), total-ERK (9102, Cell Signaling), pAKT (4060, Cell Signaling), total-AKT (4685, Cell Signaling), pSTAT3 (9145, Cell Signaling), STAT3 (sc-7179, Santa Cruz), p65 (sc-372, Santa Cruz), PARP (9532, Cell Signaling), GAPDH (TA-8, Beijing ZhongShan Golden Bridge Biotechnology Co., China), or β-catenin (ab32572,
Abcam). Western blots were exposed to X-ray films or scanned with an ImageQuant LAS 4000 mini (GE healthcare).

Quantitative real-time PCR

mRNA was extracted from tumors of Kras^{G12D} and Kras^{G12D}; IL-6^{-} mice 32 weeks post-infection and Kras^{G12D}; p53^{floxed}/Kras^{G12D}; p53^{floxed} mice around 16 weeks post-infection for analysis. 2 μg total RNA was reverse transcribed to cDNA using SuperRT cDNA synthesis kit (Beijing CoWin Biosciences Co., Ltd., China). Real-time PCR was performed using the BioRad iQ5 Realtime PCR system and StepOnePlus Realtime PCR system (ABI) with Realtime PCR Master Mix containing SYBR Green (QPk-201, TOYOBO, Japan) and unique primers (Table S1). Three to four samples for each group were analyzed. Gene expression results were normalized to β-actin mRNA.

Statistical analysis

The Student’s t-test was used to evaluate lesion number and number of BrdU or Ki67- positive cells. Fisher’s exact test was normally [38], and did not show lung tumors through 54 weeks survival time. Expression differences among four groups were analyzed by ANOVA. P<0.05 was considered statistically significant.

Results

IL-6 deletion accelerates oncogenic Kras^{G12D}-induced lung tumorigenesis

As previously described, Kras^{G12D} mice developed lung tumors following a long latency [39]. IL-6^{-} mice developed normally [38], and did not show lung tumors through 54 weeks of age (data not shown). Following adeno-Cre inhalation, PCR analysis confirmed recombination of the conditional Kras^{G12D} allele (Figure S1). Kras^{G12D}; IL-6^{-} mice had a median survival of 37 weeks after adeno-Cre inoculation, significantly longer than Kras^{G12D} mice (P<0.0001) (Table 1). Mice were euthanized at 2, 4, 20, 28, and 32 weeks post-infection, and lung lesions in H&E-stained sections were analyzed at each time point. At 2 weeks post-infection (n = 3), both Kras^{G12D} and Kras^{G12D}; IL-6^{-} mice had early lung lesions. At 4 weeks post-infection, Kras^{G12D}; IL-6^{-} mice had more early lung lesions than Kras^{G12D} mice (Figure 1A-C). These lesions were atypical adenomatous hyperplasia (AAH) and epithelial hyperplasia (EH) of the bronchioles, as reported previously [39].

IL-6 deletion retards oncogenic Kras^{G12D}-induced lung tumor progression

At 20 weeks post-infection, lung tumors in Kras^{G12D}; IL-6^{-} mice were modestly smaller and less dense than those in Kras^{G12D} mice (Figure 1D and E). At 28 weeks post-infection, in comparison with Kras^{G12D} mice, more lesions were observed in Kras^{G12D}; IL-6^{-} mice with the majority of lesions in early stages of tumor development (Figure 1F). However, tumors 3-10 mm in diameter were observed in lungs of Kras^{G12D} mice, while the majority of Kras^{G12D}; IL-6^{-} lung tumors were less than 1.5 mm (Figure 1G-I). Further, although IL-6 signaling promotes skin tumor growth and angiogenesis in a paracrine fashion [4], we did not detect any difference between Kras^{G12D} and Kras^{G12D}; IL-6^{-} mice after immunohistochemical staining with Endomucin, a microvessel density marker to measure angiogenesis index (Figure 1J and K).

IL-6 deletion attenuates lung tumor proliferation

To determine whether tumor proliferation is affected by IL-6 deletion in vivo, we measured BrdU-labeling cells in lung tumors. Significantly fewer labeled nuclei were observed in lung sections from Kras^{G12D}; IL-6^{-} mice 20 weeks post-infection with adeno-Cre compared with those derived from control Kras^{G12D} mice (Figure 2A-C). Similar results were observed from Ki67 staining in lung sections from Kras^{G12D} and Kras^{G12D}; IL-6^{-} mice 28 weeks post-infection with adeno-Cre (Figure S2). Expression of pERK, which acts downstream of Kras and is accompanied by lung tumors following a long latency [39], therefore, Kras^{G12D}; p53^{floxed} mice had significantly longer survival than Kras^{G12D}; p53^{floxed} mice (P<0.01). * Median latency shown is after adeno-Cre treatment at 6-10 weeks of age, estimated by Kaplan–Meier analysis.

doi: 10.1371/journal.pone.0080885.t001

| Genotype               | Number treated | Median survival range (weeks) |
|------------------------|----------------|-------------------------------|
| Kras^{G12D}           | 13             | >54                           |
| Kras^{G12D}; IL-6^{-}  | 14             | 34.6                          |
| Kras^{G12D}; IL-6^{-}  | 38             | 37.9                          |
| p53^{floxed}          | 8              | >52                           |
| p53^{floxed}          | 9              | >52                           |
| Kras^{G12D}; p53^{floxed}; IL-6^{-} | 43 | 16.3                          |
| Kras^{G12D}; p53^{floxed}; IL-6^{-} | 44 | 17.4                          |

2 Kras^{G12D}; IL-6^{-} mice had significantly longer survival than Kras^{G12D} mice (P<0.0001). * Kras^{G12D}; p53^{floxed}; IL-6^{-} mice had significantly longer survival than Kras^{G12D}; p53^{floxed} mice (P<0.01). * Median latency shown is after adeno-Cre treatment at 6-10 weeks of age, estimated by Kaplan–Meier analysis.

IL-6 deletion extends survival of Kras^{G12D}; p53^{floxed} mice

As previously reported, no metastases or local invasions were detected in Kras^{G12D} mice [39], and similar results were observed in Kras^{G12D}; IL-6^{-} mice. Kras^{G12D} activation accompanied by p53 deletion can cause lung tumor metastasis [37], therefore, Kras^{G12D}; p53^{floxed}; IL-6^{-} mice were generated to investigate the influence of IL-6 deletion on lung cancer metastasis.

p53 allelic recombination was confirmed by PCR (Figure S3). IL-6 deletion increased median survival of Kras^{G12D}; p53^{floxed} mice (P<0.01) (Table 1) despite substantial lung tumor burden in both Kras^{G12D}; p53^{floxed} and Kras^{G12D}; p53^{floxed}; IL-6^{-} mice 12 weeks post-infection (Figure 3A and B). BrdU staining indicated both groups of lung tumors were highly proliferative (Figure 3C and D), and pERK expression was high in both groups (Figure 3E and F); no statistical differences were observed.
For comparison, 17 Kras\textsuperscript{G12D}; p53\textsuperscript{flox/flox}; IL-6\textsuperscript{-/-} mice and 19 Kras\textsuperscript{G12D}; p53\textsuperscript{flox/flox} mice were analyzed for metastases around 16 weeks post-infection with adeno-Cre (Table 2). Histologically, metastases were found in 5 of 17 Kras\textsuperscript{G12D}; p53\textsuperscript{flox/flox}; IL-6\textsuperscript{-/-} mice (29.4%) and 10 of 19 Kras\textsuperscript{G12D}; p53\textsuperscript{flox/flox} mice (52.6%), although this difference was not significant (\( P=0.19 \)). Metastatic lesions to the parietal pleura, thymus (Figure S4A and B), and lymph nodes were observed in both Kras\textsuperscript{G12D}; p53\textsuperscript{flox/flox} and Kras\textsuperscript{G12D}; p53\textsuperscript{flox/flox}; IL-6\textsuperscript{-/-} mice (Figure 3G and H). Heart metastases (Figure S4C) were observed in 2 of 19 Kras\textsuperscript{G12D}; p53\textsuperscript{flox/flox} mice (Table 2).

**IL-6 deletion alters, but p53 deletion attenuates, some inflammatory cytokines**

To investigate whether IL-6 deletion affected inflammation, we measured macrophage density using MAC2 staining [41]. No significant changes in macrophage number were observed among tumors from Kras\textsuperscript{G12D}, Kras\textsuperscript{G12D}; IL-6\textsuperscript{-/-}, Kras\textsuperscript{G12D}; p53\textsuperscript{flox/flox}, and Kras\textsuperscript{G12D}; p53\textsuperscript{flox/flox}; IL-6\textsuperscript{-/-} mice (Figure 4A-E). We also measured no change in CD3 expression, a T cell marker, in any of the four tumor groups (Figure S5B).

Several cytokines play important roles in the inflammatory process. The list includes IL-1, TNF\alpha, and IL-6. Chemokines represent the largest family of cytokines and are classified into polypeptide groups by the location of cysteine residues near the amino terminus (e.g., C-C, C-X-C, or CX3C) [42].

**Figure 1. IL-6 deletion promotes tumorigenesis but retards tumor progression of Kras\textsuperscript{G12D}-driven lung cancer.** (A and B) Representative images of H&E-stained lung tissue sections from (A) K and (B) KI mice 4 weeks post-infection with adeno-Cre. Arrows indicate early lesions. (C) Quantification of lesions in K (\( n=3 \)) and KI (\( n=5 \)) mice 4 weeks post-infection with adeno-Cre. Data are shown as mean \( \pm \) s.e.m. **\( P<0.01 \). (D and E) Representative images of H&E-stained lung tissue sections from (D) K and (E) KI mice 20 weeks post-infection with adeno-Cre. (F) Quantification of small lesions (<1.5 mm) in K and KI mice (\( n=6 \)) 28 weeks post-infection with adeno-Cre. Data shown are mean \( \pm \) s.e.m. *\( P<0.05 \). (G and H) Representative images of H&E-stained lung tissue sections from (G) K and (H) KI mice 28 weeks post-infection with adeno-Cre. Arrow indicates a large tumor. (I) Quantification of large tumors (>1.5 mm) in K and KI mice (\( n=6 \)) 28 weeks post-infection with adeno-Cre. Data shown are mean \( \pm \) s.e.m. **\( P<0.01 \). (J and K) Representative images of Endomucin-stained lung tissue sections from (J) K and (K) KI mice 28 weeks post-infection with adeno-Cre. Scale bar indicates 500 \( \mu \)m in (A, B, D, E, G and H), or 100 \( \mu \)m in (J and K). Abbreviations: K=Kras\textsuperscript{G12D}, KI=Kras\textsuperscript{G12D}; IL-6\textsuperscript{-/-}.

doi: 10.1371/journal.pone.0080885.g001
Oncogenic Ras induces the secretion of the ELR1 + CXC chemokine family to promote tumorigenesis [43]. Some chemokines and growth factors are involved in tumor progression [42], so we screened inflammatory cytokine changes in tumors with real-time PCR. Three samples each tumor group were used to perform real-time PCR without replicate. There were no significant differences found for IL-1α, CXCL-1, CXCL-5, CXCL-9, CXCL-12, CXCL-16, TGF-β2, BMP2, BMP4, CCL-2, CCL-7, CCL-8, CCL-9, CCL-22, CCL-28 and CX3CL-1 expression among four groups of tumors (Figure S5). The screening results showed some changing trends in some inflammatory cytokines (Figure S5). We confirmed the changes using triplicate real-time PCR reactions with 3 to 4 samples in each group. Elevated expression of TNFα and reduced expression of CCL-19 and CCL-20 were detected in tumors from \( Kras^{G12D}; IL-6^{-/-} \) mice compared to \( Kras^{G12D} \) mice. However, these changes were absent between tumors from \( Kras^{G12D}; p53^{flox/flox} \) and \( Kras^{G12D}; p53^{flox/flox}; IL-6^{-/-} \) mice. While no statistical differences in IL-1β, CCL-7, CCL-8, CCL-24 and CXCL-5 gene expression were confirmed among four tumor groups (Figure 4F and G).

We also examined the nuclear localization of NF-κB subunit p65, which is important in cancer-related inflammation and malignant progression [44,45]. However, no significant localization change was observed among tumors from the four genotypes (Figure S6). And no dramatic change was observed in β-catenin expression in nucleus (Figure S6), which is related to lung cancer development [46]. Expression of pSTAT3, which is the main downstream target of IL-6, was reduced in some \( Kras^{G12D}; IL-6^{-/-} \) tumors (Figure 5) but increased in \( p53^{-/-} \) deleted tumors. These data indicated that IL-6 deletion altered tumor expression of some inflammatory cytokines, although these changes were weakened by \( p53 \) deletion.

**Discussion**

Previous studies have shown that carcinogen-induced tumorigenesis in IL-6\(^{-/-}\) mice is delayed by 1-2 weeks [4,47]; however, we found no difference in \( Kras^{G12D} \)-induced tumor onset regardless of IL-6 deficiency. One possible explanation is that \( Kras^{G12D} \) activation may induce lung tumorigenesis more robustly than other carcinogens.

Some inflammatory cytokines are associated with tumor progression [42]. TNFα may act as a tumor promoter by regulating a cascade of cytokines, chemokines, adhesions, matrix metalloproteinases (MMPs) and pro-angiogenic activities [2,48]. In this study, IL-6 deletion in \( Kras^{G12D} \) tumors upregulated TNFα expression. Elevated expression of TNFα may compensate for the loss of IL-6 and thus increase tumorigenesis. However, tumor progression is delayed in \( Kras^{G12D}; IL-6^{-/-} \) mice, consistent with previous results [4,47]. These data indicate that IL-6 is important for tumor progression in vivo and suggest that IL-6 inhibition may have biphasic stage-specific effects in lung cancer, enhancing tumorigenesis early while suppressing tumor progression later. Consequently,
this may pose a risk to lung cancer patients treated with IL-6-targeted therapy.

CCL-20 (or macrophage pro-inflammatory chemokine-3α, MIP-3α), a C-C motif chemokine, is overexpressed in pancreatic carcinoma cells and stimulates growth of tumor cells [49]. CCL-19 (or macrophage inflammatory protein-3 beta, MIP-3β), plays an important role in the migration of mature dendritic cells and T-cells [50]. Both dendritic cells and T-cells are double-edged swords in the tumor microenvironment, in addition to initiating potent anti-tumor immune responses, these cells may also stimulate cancerous cell growth and spreading [51,52]. Persistently activated or tyrosine-phosphorylated STAT3 (pSTAT3) is found in 50% of lung adenocarcinomas [53,54]. pSTAT3 can enhance tumor proliferation and loss of pSTAT3 arrests growth of premalignant lesions, almost abrogating the development of advanced tumors [55]. In this study, IL-6 deletion in Kras<sup>G12D</sup>; p53<sup>flox/flox</sup> tumors resulted in downregulation of pSTAT3, CCL-19 and CCL-20. pERK expression was reduced in Kras<sup>G12D</sup>; IL-6<sup>-/-</sup> tumors 20 weeks post-infection (Figure 2), but increased in most Kras<sup>G12D</sup>; IL-6<sup>-/-</sup> tumors 32 weeks post-infection (Figure 5). These data suggest that early stage, tumor growth may be delayed by low expression of pERK, pSTAT3 and CCL-20. During later stages, tumor growth may be induced by upregulation of pERK and TNFα, although these mechanisms need further study.

Table 2. Site and frequency of metastases from primary lung tumors.

| Sites of metastases | Kras<sup>G12D</sup>; p53<sup>flox/flox</sup> | Kras<sup>G12D</sup>; p53<sup>flox/flox</sup>; IL-6<sup>-/-</sup> |
|---------------------|---------------------------------|---------------------------------|
| Lymph node          | 10 of 19 (52.6%)                | 5 of 17 (29.4%)                |
| Thymus              | 1 of 19 (5.3%)                  | 1 of 17 (5.9%)                 |
| Heart               | 2 of 19 (10.5%)                 | 0 of 17                        |

doi: 10.1371/journal.pone.0080885.t002

doi: 10.1371/journal.pone.0080885.g003

Figure 3. <i>KP</i> and <i>KPI</i> mice have high tumor burden, tumor cell proliferation and metastases. Representative images of lungs (A and B), BrdU staining (C and D), pERK staining (E and F) and tumor metastases (G and H) from <i>KP</i> (A, C, E, and G) and <i>KPI</i> (B, D, F, and H) mice 12 weeks post-infection with adeno-Cre. Dotted lines (G and H) show metastatic tumor edges. Asterisks indicate center of metastatic tumors. Scale bar indicates 500 μm (A, B, G, and H), 50 μm (C and D) or 100 μm (E and F). Abbreviations: KP=Kras<sup>G12D</sup>; p53<sup>flox/flox</sup>, KPI=Kras<sup>G12D</sup>; p53<sup>flox/flox</sup>; IL-6<sup>-/-</sup>.

Abbreviations: KP=Kras<sup>G12D</sup>; p53<sup>flox/flox</sup>, KPI=Kras<sup>G12D</sup>; p53<sup>flox/flox</sup>; IL-6<sup>-/-</sup>.
Our data show that p53 deletion more dramatically affected Kras\(^{G12D}\)-induced lung cancer than IL-6 deletion. To a large extent, p53 deletion attenuated the effects of IL-6 deletion on delayed tumor growth and prolonged survival. p53 deletion enhanced pSTAT3 expression (Figure 5) and abrogated the change in CCL-20 expression in Kras\(^{G12D}\); p53\(^{flox/flox}\); IL-6\(^{-/-}\) tumors (Figure 4). p53 deletion also increased expression of pAKT and total-AKT expression, which are associated with high proliferation, in Kras\(^{G12D}\); p53\(^{flox/flox}\) and Kras\(^{G12D}\); p53\(^{flox/flox}\); IL-6\(^{-/-}\) tumors (Figure 5). p53 deletion may attenuate the effects of IL-6 deletion through these pathways.

We observed a trend for reduced metastases with IL-6 deletion (Table 2), although additional samples are required to confirm this result. Separately, we have observed dramatically increased IL-6 expression in primary and metastatic tumors from mice with high metastatic rates (unpublished data), similar to the report that IL-6 promotes cancer cells to metastasize to distant sites [30,31]. Furthermore, survival time of Kras\(^{G12D}\); p53\(^{flox/flox}\); IL-6\(^{-/-}\) mice was significantly extended (\(P < 0.01\)) (Table 1). These results indicate that IL-6 deletion may reduce lung cancer metastases and prolong survival time in vivo although p53 deletion dominantly impacts the evolution of Kras\(^{G12D}\) lung cancer.

The involvement of inflammation in tumorigenesis, progression, and metastasis is widely accepted; however, whether IL-6-targeted therapies will prolong the survival time of lung cancer patients remains uncertain. Our results indicate anti-IL-6 therapies may have some success in clinical trials. For example, when NSCLC has not metastasized, IL-6 inhibition may prolong survival but increase the risk of further tumorigenesis; if metastasized, IL-6 inhibition may only moderately impact metastasis but may lengthen survival time. Further studies are needed to elucidate these possibilities. In summary, our results provide evidence that IL-6 deficiency promotes lung tumorigenesis, but suppresses tumor progression and elongates survival in vivo. However, these effects can be attenuated by p53 deletion.

**Figure 4.** IL-6 deletion upregulates TNFα and downregulates CCL-19 and CCL-20 in tumors. (A-D) Representative images of MAC2-stained lung tissue sections from (A) K and (B) KI mice 28 weeks post-infection and from (C) KP and (D) KPI mice 12 weeks post-infection with adeno-Cre. (E) Quantification of MAC2-positive macrophages in lung tumors from K, KI, KP, and KPI mice (n=3). No statistical difference was observed. (F and G) Gene expression of IL-1β, TNFα, CCL-7, CCL-19, CCL-20, CXCL-5, CCL-8, and CCL-24 in tumors from K, KI, KP, and KPI mice were determined by real-time PCR. Three to four tumors for each group were detected and triplicate PCRs were performed. Gene expression was normalized to β-actin mRNA. * \(P<0.05\) vs. K tumors. Abbreviations: K=Kras\(^{G12D}\), KI=Kras\(^{G12D}\); IL-6\(^{-/-}\), KP=Kras\(^{G12D}\); p53\(^{flox/flox}\), KPI=Kras\(^{G12D}\); p53\(^{flox/flox}\); IL-6\(^{-/-}\).

doi: 10.1371/journal.pone.0080885.g004
Figure 5. **p53 deletion Increases pSTAT3 and pAKT expression in KrasG12D tumors.** Tumor lysates were extracted from K and KI mice 32 weeks post-infection and from KP and KPI mice 15 weeks post-infection for Western blot analysis. Western blot results of pSTAT3 and total-STAT3 were scanned by an ImageQuant LAS 4000mini (GE healthcare). Other results were exposed to X-ray films. Abbreviations: K=KrasG12D, KI=KrasG12D, IL-6−/−, KP=KrasG12D, p53floxflox, KPI=KrasG12D, p53floxflox, IL-6−/−.

doi: 10.1371/journal.pone.0080885.g005
p53 Loss Attenuates effects of IL-6 Inhibition

Supporting Information

Figure S1. PCR analysis of Kras allelic recombination. A 500 bp PCR product represents the floxed, unrecombined Kras<sup>G12D</sup> allele; a 622 bp fragment represents the wildtype Kras allele; and a 650 bp fragment represents a recombined Kras<sup>G12D</sup> allele after removal of floxed stop cassette by adeno-Cre. K, KI, KP, and KPI mice were treated with adeno-Cre and the 650 bp recombined band revealed. Abbreviations: WT= wildtype lungs. Floxed= floxed Kras<sup>G12D</sup> without adeno-Cre treatment. K=Kras<sup>G12D</sup>, KI=Kras<sup>G12D</sup>; IL-6<sup>−/−</sup>. KP=Kras<sup>G12D</sup>; p53<sup>flox/flox</sup>. KPI=Kras<sup>G12D</sup>; p53<sup>flox/flox</sup>; IL-6<sup>−/−</sup>. (TIF)

Figure S2. IL-6 deletion attenuates tumor proliferation determined by Ki67 staining. (A and B) Representative images of Ki67-stained lung tissue sections from (A) K and (B) KI mice 28 weeks post-infection with adeno-Cre. (C) Quantification of Ki67-positive tumor cells in lung tissue sections of K and KI mice (n=3). ** P<0.01. Scale bar indicates 50 μm. Abbreviations: K=Kras<sup>G12D</sup>. KI=Kras<sup>G12D</sup>; IL-6<sup>−/−</sup>. (TIF)

Figure S3. PCR analysis of p53 allelic recombination. A 212 bp PCR product represents the floxed, unrecombined p53 allele; a 168 bp fragment represents the recombined allele after inoculation with adeno-Cre; and a 130 bp fragment represents the wildtype p53 allele. K, KI, KP, and KPI mice were treated with adeno-Cre. The 168 bp recombined band was showed in KP and KPI mice and 212 bp fragment remained due to tumor stromal cells. Abbreviations: WT= wildtype lungs. Floxed= floxed p53, without adeno-Cre treatment. K=Kras<sup>G12D</sup>, KI=Kras<sup>G12D</sup>; IL-6<sup>−/−</sup>. KP=Kras<sup>G12D</sup>; p53<sup>flox/flox</sup>. KPI=Kras<sup>G12D</sup>; p53<sup>flox/flox</sup>; IL-6<sup>−/−</sup>. (TIF)

Figure S4. KP and KPI mice develop metastatic lesions. (A and B) Representative images of metastatic lesions to the (A) pleura, (B) thymus in KPI mice 15 weeks post-infection with adeno-Cre. Dotted lines in the images indicate metastatic tumor edges. Asterisks indicate center of metastatic tumors. (C) Representative image of heart metastases in KP mice 14 weeks post-infection with adeno-Cre. Metastatic lesions in the heart are left of the dotted line. Scale bar indicates 200 μm (A) or 100 μm (B and C). Abbreviations: KP=Kras<sup>G12D</sup>; p53<sup>flox/flox</sup>. KPI=Kras<sup>G12D</sup>; p53<sup>flox/flox</sup>; IL-6<sup>−/−</sup>. (TIF)

Figure S5. Real-time PCR screen of changes in inflammatory cytokines levels. Three tumors from each genotype were analyzed by real-time PCR without replicate for expression of the indicated cytokine. Gene expression was normalized to β-actin mRNA. * P<0.05 vs. K tumors. # P<0.05 vs. KP tumors. Abbreviations: K=Kras<sup>G12D</sup>. KI=Kras<sup>G12D</sup>; IL-6<sup>−/−</sup>. KP=Kras<sup>G12D</sup>; p53<sup>flox/flox</sup>. KPI=Kras<sup>G12D</sup>; p53<sup>flox/flox</sup>; IL-6<sup>−/−</sup>. (TIF)

Figure S6. Nuclear localization of p65 and β-catenin are unchanged. Tumors from each mouse genotype were lysed to obtain cytoplasmic (C) and nuclear (N) fractions. Lysates were analyzed for the presence of nuclear p65 and β-catenin by Western blot. Fraction purity was determined by GAPDH (cytoplasmic) and PARP (nuclear) blots. Abbreviations: K=Kras<sup>G12D</sup>. KI=Kras<sup>G12D</sup>; IL-6<sup>−/−</sup>. KP=Kras<sup>G12D</sup>; p53<sup>flox/flox</sup>. KPI=Kras<sup>G12D</sup>; p53<sup>flox/flox</sup>; IL-6<sup>−/−</sup>. (TFF)

Table S1. Primers for real-time PCR analysis of gene expression. (DOCX)

Acknowledgements

The authors thank Ms. Mei Zheng for technical assistance.

Author Contributions

Conceived and designed the experiments: XT J Carretero XY KKW.Performed the experiments: XT ZC JY HY. Contributed reagents/materials/analysis tools: CT XC NH. Wrote the manuscript: XT XY KKW.

References

1. Ballaz S, Mulshine JL (2003) The potential contributions of chronic inflammation to lung carcinogenesis. Clin Lung Cancer 5: 46-62. doi: 10.3816/CLC.2003.n.021. PubMed: 14596704.
2. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357: 539-545. doi: 10.1016/S0140-6736(00)04046-0. PubMed: 11229684.
3. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357: 539-545. doi: 10.1016/S0140-6736(00)04046-0. PubMed: 11229684.
4. Ballys T, Smith JT, Schuster M, Dragnev KH, Rigas JR (2011) A humanized anti-IL-6 antibody (ALDS18) in non-small cell lung cancer. Expert Opin Biol Ther 11: 1663-1668. doi: 10.1517/14712598.2011.627850. PubMed: 21995322.
5. Ancrile B, Lim KH, Counter CM (2007) Oncogenic Ras-induced secretion of ILS is required for tumorigenesis. Genes Dev 21: 1714-1719. doi: 10.1101/gad.1549407. PubMed: 17633077.
6. Keller ET, Wanagat J, Ershler WB (1996) Molecular and cellular biology of interleukin-6 and its receptor. Front Biosci 1: d340-d357. PubMed: 9159238.
7. Chen J, Liu RY, Yang L, Zhao J, Zhao X et al. (2013) A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk. J Cancer Res Clin Oncol 139: 231-242. doi: 10.1007/s00432-012-1314-z. PubMed: 23052692.
8. Heikkilä K, Harris R, Lowe G, Rumley A, Yarnell J et al. (2009) Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 20: 15-26. doi: 10.1007/s10552-008-9212-z. PubMed: 18704713.
9. Bai L, Yu H, Wang H, Su H, Zhao J et al. (2013) Genetic single-nucleotide polymorphisms of inflammation-related factors associated with risk of lung cancer. Med Oncol 30: 414. doi:10.1007/s12032-012-0414-6. PubMed: 23292870.
10. Carpagno GE, Resta O, Foschino-Barbaro MP, Gramicioni E, Carpagno F (2002) Interleukin-6 is increased in breath condensate of patients with non-small cell lung cancer. Int J Biol Markers 17: 141-145. PubMed: 12113582.
11. Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S et al. (1995) Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer 71: 1095-1098. doi:10.1038/bjc.1995.212. PubMed: 7734307.
IL-6 and VEGF in small cell lung cancer patients. Anticancer prognostic markers for non-small cell lung cancer. Anticancer Res 32: 310-316. PubMed: 22552503.

Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 11: 22:4:353. PubMed: 16260852. doi: 10.1385/MO:22:4:353 PubMed: 16260852.

Severe local recurrent response to chemo-immunotherapy in advanced non-small cell lung cancer patients treated with chemotherapy. J Natl Cancer 132: 1977-1985. doi:10.1002/jjc.27982. PubMed: 23034889.

Significance of the correlation between the expression of interleukin 6 and clinical features in patients with non-small cell lung cancer. Int J Surg Pathol 20: 233-239. doi:10.1176/appj.1969.114.438274. PubMed: 22334615.

Severely limits of IFN-gamma, acute phase response and nutritional status as prognostic factors in lung cancer. Int J Surg Pathol 20: 233-239. doi:10.1176/appj.1969.114.438274. PubMed: 22334615.

Yi H, Cho HJ, Cho SM, Jo K, Park JA et al. (2012) Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells. Int J Oncol 41: 310-316. PubMed: 22552503.

Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE (2008) Drug-selected lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLOS ONE 3: e3077. doi: 10.1371/journal.pone.0003077. PubMed: 18728788.

Hsu HS, Lin JH, Hsu TW, Su K, Wang CW et al. (2012) Mesenchymal stem cells enhance lung cancer initiation through activation of IL-6/JAK-STAT3 pathway. Lung Cancer 75: 167-177. doi: 10.1016/j.lungcan.2011.07.001. PubMed: 21802163.

Tawara K, Oxford JT, Jorcyk CL (2011) Clinical significance of interleukin (IL-6) in cancer metastasis to bone: potential of anti IL-6 therapies. Cancer Manag Res 3: 177-189. PubMed: 21625400.

Yi H, Cho HJ, Cho SM, Jo K, Park JA et al. (2012) Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells. Int J Oncol 41: 310-316. PubMed: 22552503.

Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE (2008) Drug-selected lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLOS ONE 3: e3077. doi: 10.1371/journal.pone.0003077. PubMed: 18728788.

Hsu HS, Lin JH, Hsu TW, Su K, Wang CW et al. (2012) Mesenchymal stem cells enhance lung cancer initiation through activation of IL-6/JAK-STAT3 pathway. Lung Cancer 75: 167-177. doi: 10.1016/j.lungcan.2011.07.001. PubMed: 21802163.

Tawara K, Oxford JT, Jorcyk CL (2011) Clinical significance of interleukin (IL-6) in cancer metastasis to bone: potential of anti IL-6 therapies. Cancer Manag Res 3: 177-189. PubMed: 21625400.

Yi H, Cho HJ, Cho SM, Jo K, Park JA et al. (2012) Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells. Int J Oncol 41: 310-316. PubMed: 22552503.

Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE (2008) Drug-selected lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLOS ONE 3: e3077. doi: 10.1371/journal.pone.0003077. PubMed: 18728788.
53. Mukohara T, Kudoh S, Yamauchi S, Kimura T, Yoshimura N et al. (2003) Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer 41: 123-130. doi:10.1016/S0169-5002(03)00156-9. PubMed: 12871775.

54. Seki Y, Suzuki N, Imaizumi M, Iwamoto T, Usami N et al. (2004) STAT3 and MAPK in human lung cancer tissues and suppression of oncogenic growth by JAB and dominant negative STAT3. Int J Oncol 24: 931-934. PubMed: 15010832.

55. Bollrath J, Greten FR (2009) IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 10: 1314-1319. doi:10.1038/embor.2009.243. PubMed: 19893576.